Highest-materiality recent filing
CalciMedica raises ~$15M in private placement; FDA clears continued Auxora development
Private placement of 18.7M units at $0.8033 each; gross proceeds ~$15M, up to $34M additional from warrant exercises.
CalciMedica amends loan with Avenue: extends maturity to 2029, ups convertible amount to $3M
Loan principal $10M unchanged; interest-only extended to Sep 2027, maturity to Sep 2029.
CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026
Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.
CalciMedica receives Nasdaq delisting notices for MVLS and bid price deficiencies
Nasdaq notified CalciMedica on Mar 13, 2026 that MVLS was below $35M for 30 consecutive business days.
CalciMedica reports 2025 net loss $29.6M; cash $13M; KOURAGE safety review finds no drug toxicity
Net loss $29.6M ($1.97/share) vs $13.7M ($1.22/share) in 2024; R&D expense $15.2M, G&A $7.9M.
CalciMedica discontinues Phase 2 KOURAGE trial of Auxora in AKI after IDMC safety concern
IDMC identified a safety concern requiring re-evaluation of study design, particularly enrollment criteria.
CalciMedica discontinues Phase 2 KOURAGE trial, extends cash runway to Q4 2026
Phase 2 KOURAGE trial discontinued following IDMC recommendation.
CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026
Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.
CalciMedica Q1 2025 net loss $5.9M; cash $24.6M; KOURAGE trial data due end of 2025
Net loss of $5.9M in Q1 2025 vs. net income of $0.1M in Q1 2024; R&D expenses rose to $4.2M.
Loan agreement with Avenue Venture Opportunities Fund II provides up to $32.5M; initial tranche $10M funded Feb 28, 2025.
CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial
In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.
CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026
Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.
CalciMedica appoints Stephen Bardin as CFO; Dan Geffken resigns as interim CFO
Dan Geffken resigned as interim CFO effective after filing Q3 2024 10-Q.
CalciMedica prices public offering of 2.72M shares at $3.75, raising $10.2M
Pricing of 2,720,000 shares at $3.75/share for gross proceeds of $10.2M.
100% relative risk reduction (p=0.0027) in new-onset severe respiratory failure for combined high/medium dose vs low dose/placebo.
CalciMedica announces proposed public offering of common stock; preliminary cash $14.6M
Launched underwritten public offering of common stock; all shares sold by the company; no terms disclosed.
CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data
Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.
CalciMedica announces positive Phase 2b CARPO topline data for Auxora in acute pancreatitis
Trial enrolled 216 patients; primary endpoint met with up to 43.6% relative risk reduction in time to solid food tolerance vs placebo in hyper-inflamed subgroup.
CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025
Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.
Dismissed Ernst & Young LLP on April 5, 2024; engaged Moss Adams LLP on April 9, 2024 for FY2024 audit.
CalciMedica increases ATM offering capacity from $4.7M to $17.1M
Increased maximum aggregate offering price under ATM agreement with H.C. Wainwright to $17,068,386.
CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024
Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.
FDA clears CalciMedica IND for Auxora Phase 2 KOURAGE trial in severe AKI with AHRF
FDA cleared IND for KOURAGE Phase 2 trial of Auxora in stage 2/3 AKI with AHRF; enrollment starts H1 2024, data expected 2025.
CalciMedica corrects private placement terms; raises up to ~$55M for clinical trials
Corrected offering: 4,985,610 shares, 306,506 pre-funded warrants, 5,292,116 common warrants at $3.827/unit.
CalciMedica raises up to $55M in private placement; $20.4M upfront from new and existing investors
Upfront gross proceeds $20.4M from sale of 5.1M shares and pre-funded warrants to purchase 351,352 shares at $3.70/share.
CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial
Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.
CalciMedica reports $14.6M cash; Auxora shows 53% hospital stay reduction in CRSPA cohort
Preliminary cash, equivalents, and short-term investments of $14.6M as of Sept 30, 2023; expected to fund operations through Q3 2024.
CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials
CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.
Net loss $6.3M ($1.11/sh) in Q2 2023; cash $19.1M expected to fund operations for at least 12 months.
CalciMedica receives Nasdaq approval, relisting starts June 14, 2023 under CALC
Nasdaq approved relisting on Capital Market; trading begins June 14, 2023.
CalciMedica Q1 net loss $19.3M ($23.43/sh); cash $34.2M; Nasdaq delisted
Net loss $19.3M ($23.43 diluted EPS); operating expenses $22.3M incl. $16.2M one-time Graybug merger costs.
CalciMedica restates FY2022 results; net loss cut $6.7M on valuation errors
Board concluded on May 8, 2023 that FY2022 financials contained errors in convertible note and warrant liability valuations.
CalciMedica restates FY2022 financials due to errors in convertible note and warrant valuation
Board concluded Dec 31, 2022 financial statements should no longer be relied upon.
CalciMedica delisted from Nasdaq, now trading on OTCQB after failing initial listing requirements
Received Nasdaq delisting notice on March 21, 2023 for not meeting initial listing requirements after merger.
Merger closed March 20, 2023; 3.95M shares issued to CalciMedica stockholders; CalciMedica equityholders own ~72% of combined company.
Graybug stockholders approve merger with CalciMedica; 14-to-1 reverse split effective Mar 17
All five proposals approved: share issuance (13.2M for), charter amendment, equity plan, ESPP, and adjournment.
On January 13, 2025, the Company’s Board appointed Alan Glicklich, M.D., as a Class I director of the Company, effective as of the Effective Date, with a term of office expiring at the 2027 annual meeting of stockholders.
On January 10, 2025, Eric Bjerkholt tendered his resignation as a member of the board of directors (the “Board”) of CalciMedica, Inc., a Delaware corporation (the “Company”) and as Chair and a member of the audit committee of the Board, effective as of January 15, 2025 (the “Effective Date”).
Dan Geffken tendered his resignation as interim Chief Financial Officer, principal financial officer and principal accounting officer of CalciMedica, Inc.
the Company’s board of directors (the “Board”) appointed Stephen Bardin as the Company’s Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer effective as of the Effective Date.
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Allan Shaw 59 Class III Director
Eric Bjerkholt was reappointed to the Company’s board of directors as a Class I director, effective as of the effective time of the Merger.
A. Rachel Leheny, Ph.D. 59 Chief Executive Officer and Class II Director
Max materiality 0.95 · Median 0.65 · Most common event other_material